EMERYVILLE, Calif.--(BUSINESS WIRE)--BioTime, Inc. (OTCBB: BTIM) today announced financial results for the fiscal year ended December 31, 2006. BioTime’s royalties from Hextend® sales by Hospira, Inc. increased 49% to $933,478 for the year ended December 31, 2006, from $626,135 in 2005, as the number of 500mL units of Hextend sold increased by 40%. Although hospital sales increased, the largest contributing factor to the increase in royalties from 2005 was an increase in units of Hextend purchased by the U.S. Armed Forces, most of which occurred in the second half of 2006. Hextend has been purchased by the U.S. Armed Forces through intermittent large volume orders. Hextend has become the standard plasma volume expander at a number of prominent teaching hospitals and leading medical centers and is part of the Tactical Combat Casualty Care protocol.
